CovidStanfordV1, Main, Exploration, bibRecord, 000207

The immunology of SARS-CoV-2 infections and vaccines.

Identifieur interne : 000207 ( Main/Exploration ); précédent : 000206; suivant : 000208

The immunology of SARS-CoV-2 infections and vaccines.

Auteurs : Lilit Grigoryan [États-Unis] ; Bali Pulendran [États-Unis]

Source :

Seminars in immunology [ 1096-3618 ] ; 2020.

RBID : pubmed:33262067

Descripteurs français

KwdFr :
- Adjuvants immunologiques (usage thérapeutique), Adulte (MeSH), Adulte d'âge moyen (MeSH), Animaux (MeSH), Anticorps antiviraux (immunologie), Anticorps neutralisants (immunologie), Biologie des systèmes (méthodes), Conception de médicament (MeSH), Humains (MeSH), Jeune adulte (MeSH), Lymphocytes T (immunologie), Modèles animaux de maladie humaine (MeSH), Vaccinologie (méthodes).
MESH :
- immunologie : Anticorps antiviraux, Anticorps neutralisants, Lymphocytes T.
- méthodes : Biologie des systèmes, Vaccinologie.
- usage thérapeutique : Adjuvants immunologiques.
- Adulte, Adulte d'âge moyen, Animaux, Conception de médicament, Humains, Jeune adulte, Modèles animaux de maladie humaine.

English descriptors

KwdEn :
- Adjuvants, Immunologic (therapeutic use), Adult (MeSH), Animals (MeSH), Antibodies, Neutralizing (immunology), Antibodies, Viral (immunology), COVID-19 (immunology), COVID-19 (pathology), COVID-19 (prevention & control), COVID-19 Vaccines (immunology), COVID-19 Vaccines (therapeutic use), Disease Models, Animal (MeSH), Drug Design (MeSH), Humans (MeSH), Middle Aged (MeSH), SARS-CoV-2 (immunology), Systems Biology (methods), T-Lymphocytes (immunology), Vaccinology (methods), Young Adult (MeSH).
MESH :
- chemical , immunology : Antibodies, Neutralizing, Antibodies, Viral, COVID-19 Vaccines.
- chemical , therapeutic use : Adjuvants, Immunologic, COVID-19 Vaccines.
- immunology : COVID-19, SARS-CoV-2, T-Lymphocytes.
- methods : Systems Biology, Vaccinology.
- pathology : COVID-19.
- prevention & control : COVID-19.
- Adult, Animals, Disease Models, Animal, Drug Design, Humans, Middle Aged, Young Adult.

Abstract

SARS-CoV-2, the virus that causes COVID-19, emerged in late 2019, and was declared a global pandemic on March 11th 2020. With over 50 million cases and 1.2 million deaths around the world, to date, this pandemic represents the gravest global health crisis of our times. Thus, the race to develop a COVID-19 vaccine is an urgent global imperative. At the time of writing, there are over 165 vaccine candidates being developed, with 33 in various stages of clinical testing. In this review, we discuss emerging insights about the human immune response to SARS-CoV-2, and their implications for vaccine design. We then review emerging knowledge of the immunogenicity of the numerous vaccine candidates that are currently being tested in the clinic and discuss the range of immune defense mechanisms that can be harnessed to develop novel vaccines that confer durable protection against SARS-CoV-2. Finally, we conclude with a discussion of the potential role of a systems vaccinology approach in accelerating the clinical testing of vaccines, to meet the urgent needs posed by the pandemic.

DOI: 10.1016/j.smim.2020.101422
PubMed: 33262067
PubMed Central: PMC7670910

Affiliations:

États-Unis

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000134
to stream Main, to step Curation: 000134

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The immunology of SARS-CoV-2 infections and vaccines.</title>
<author><name sortKey="Grigoryan, Lilit" sort="Grigoryan, Lilit" uniqKey="Grigoryan L" first="Lilit" last="Grigoryan">Lilit Grigoryan</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute for Immunology, Transplantation and Infectious Diseases, Department of Pathology, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, 94305, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Institute for Immunology, Transplantation and Infectious Diseases, Department of Pathology, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, 94305</wicri:regionArea>
<wicri:noRegion>94305</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pulendran, Bali" sort="Pulendran, Bali" uniqKey="Pulendran B" first="Bali" last="Pulendran">Bali Pulendran</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute for Immunology, Transplantation and Infectious Diseases, Department of Pathology, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, 94305, United States. Electronic address: bpulend@stanford.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Institute for Immunology, Transplantation and Infectious Diseases, Department of Pathology, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, 94305</wicri:regionArea>
<wicri:noRegion>94305</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:33262067</idno>
<idno type="pmid">33262067</idno>
<idno type="doi">10.1016/j.smim.2020.101422</idno>
<idno type="pmc">PMC7670910</idno>
<idno type="wicri:Area/Main/Corpus">000134</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000134</idno>
<idno type="wicri:Area/Main/Curation">000134</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000134</idno>
<idno type="wicri:Area/Main/Exploration">000134</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The immunology of SARS-CoV-2 infections and vaccines.</title>
<author><name sortKey="Grigoryan, Lilit" sort="Grigoryan, Lilit" uniqKey="Grigoryan L" first="Lilit" last="Grigoryan">Lilit Grigoryan</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute for Immunology, Transplantation and Infectious Diseases, Department of Pathology, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, 94305, United States.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Institute for Immunology, Transplantation and Infectious Diseases, Department of Pathology, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, 94305</wicri:regionArea>
<wicri:noRegion>94305</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pulendran, Bali" sort="Pulendran, Bali" uniqKey="Pulendran B" first="Bali" last="Pulendran">Bali Pulendran</name>
<affiliation wicri:level="1"><nlm:affiliation>Institute for Immunology, Transplantation and Infectious Diseases, Department of Pathology, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, 94305, United States. Electronic address: bpulend@stanford.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Institute for Immunology, Transplantation and Infectious Diseases, Department of Pathology, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, 94305</wicri:regionArea>
<wicri:noRegion>94305</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Seminars in immunology</title>
<idno type="eISSN">1096-3618</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (therapeutic use)</term>
<term>Adult (MeSH)</term>
<term>Animals (MeSH)</term>
<term>Antibodies, Neutralizing (immunology)</term>
<term>Antibodies, Viral (immunology)</term>
<term>COVID-19 (immunology)</term>
<term>COVID-19 (pathology)</term>
<term>COVID-19 (prevention & control)</term>
<term>COVID-19 Vaccines (immunology)</term>
<term>COVID-19 Vaccines (therapeutic use)</term>
<term>Disease Models, Animal (MeSH)</term>
<term>Drug Design (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>SARS-CoV-2 (immunology)</term>
<term>Systems Biology (methods)</term>
<term>T-Lymphocytes (immunology)</term>
<term>Vaccinology (methods)</term>
<term>Young Adult (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (usage thérapeutique)</term>
<term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Animaux (MeSH)</term>
<term>Anticorps antiviraux (immunologie)</term>
<term>Anticorps neutralisants (immunologie)</term>
<term>Biologie des systèmes (méthodes)</term>
<term>Conception de médicament (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Jeune adulte (MeSH)</term>
<term>Lymphocytes T (immunologie)</term>
<term>Modèles animaux de maladie humaine (MeSH)</term>
<term>Vaccinologie (méthodes)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Neutralizing</term>
<term>Antibodies, Viral</term>
<term>COVID-19 Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>COVID-19 Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Anticorps neutralisants</term>
<term>Lymphocytes T</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>COVID-19</term>
<term>SARS-CoV-2</term>
<term>T-Lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Systems Biology</term>
<term>Vaccinology</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Biologie des systèmes</term>
<term>Vaccinologie</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Adjuvants immunologiques</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Animals</term>
<term>Disease Models, Animal</term>
<term>Drug Design</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Animaux</term>
<term>Conception de médicament</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Modèles animaux de maladie humaine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">SARS-CoV-2, the virus that causes COVID-19, emerged in late 2019, and was declared a global pandemic on March 11th 2020. With over 50 million cases and 1.2 million deaths around the world, to date, this pandemic represents the gravest global health crisis of our times. Thus, the race to develop a COVID-19 vaccine is an urgent global imperative. At the time of writing, there are over 165 vaccine candidates being developed, with 33 in various stages of clinical testing. In this review, we discuss emerging insights about the human immune response to SARS-CoV-2, and their implications for vaccine design. We then review emerging knowledge of the immunogenicity of the numerous vaccine candidates that are currently being tested in the clinic and discuss the range of immune defense mechanisms that can be harnessed to develop novel vaccines that confer durable protection against SARS-CoV-2. Finally, we conclude with a discussion of the potential role of a systems vaccinology approach in accelerating the clinical testing of vaccines, to meet the urgent needs posed by the pandemic.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33262067</PMID>
<DateCompleted><Year>2021</Year>
<Month>01</Month>
<Day>04</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-3618</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>50</Volume>
<PubDate><Year>2020</Year>
<Month>08</Month>
</PubDate>
</JournalIssue>
<Title>Seminars in immunology</Title>
<ISOAbbreviation>Semin Immunol</ISOAbbreviation>
</Journal>
<ArticleTitle>The immunology of SARS-CoV-2 infections and vaccines.</ArticleTitle>
<Pagination><MedlinePgn>101422</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1044-5323(20)30038-5</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.smim.2020.101422</ELocationID>
<Abstract><AbstractText>SARS-CoV-2, the virus that causes COVID-19, emerged in late 2019, and was declared a global pandemic on March 11th 2020. With over 50 million cases and 1.2 million deaths around the world, to date, this pandemic represents the gravest global health crisis of our times. Thus, the race to develop a COVID-19 vaccine is an urgent global imperative. At the time of writing, there are over 165 vaccine candidates being developed, with 33 in various stages of clinical testing. In this review, we discuss emerging insights about the human immune response to SARS-CoV-2, and their implications for vaccine design. We then review emerging knowledge of the immunogenicity of the numerous vaccine candidates that are currently being tested in the clinic and discuss the range of immune defense mechanisms that can be harnessed to develop novel vaccines that confer durable protection against SARS-CoV-2. Finally, we conclude with a discussion of the potential role of a systems vaccinology approach in accelerating the clinical testing of vaccines, to meet the urgent needs posed by the pandemic.</AbstractText>
<CopyrightInformation>Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Grigoryan</LastName>
<ForeName>Lilit</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Institute for Immunology, Transplantation and Infectious Diseases, Department of Pathology, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, 94305, United States.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pulendran</LastName>
<ForeName>Bali</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Institute for Immunology, Transplantation and Infectious Diseases, Department of Pathology, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, 94305, United States. Electronic address: bpulend@stanford.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>U19 AI090023</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>U19 AI057266</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>11</Month>
<Day>17</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Semin Immunol</MedlineTA>
<NlmUniqueID>9009458</NlmUniqueID>
<ISSNLinking>1044-5323</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D049490" MajorTopicYN="N">Systems Biology</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000078782" MajorTopicYN="N">Vaccinology</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">Systems vaccinology</Keyword>
<Keyword MajorTopicYN="Y">Vaccines</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>09</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>11</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>12</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>1</Month>
<Day>5</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>12</Month>
<Day>2</Day>
<Hour>5</Hour>
<Minute>24</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33262067</ArticleId>
<ArticleId IdType="pii">S1044-5323(20)30038-5</ArticleId>
<ArticleId IdType="doi">10.1016/j.smim.2020.101422</ArticleId>
<ArticleId IdType="pmc">PMC7670910</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Cell. 2020 Nov 12;183(4):996-1012.e19</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33010815</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Jul 3;369(6499):77-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32376603</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Immunol. 2017 Aug 25;2(14):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28842433</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2007 Nov 8;357(19):1903-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17989383</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2007 Oct;13(10):1562-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18258008</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Aug;584(7821):437-442</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32555388</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2008 Dec 22;205(13):3119-31</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19047440</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2020 May 1;130(5):2620-2629</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32217835</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2019 Jul;571(7763):122-126</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31189952</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Aug;584(7821):457-462</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32668444</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2011 Jul 10;12(8):786-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21743478</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2014 Apr 10;157(2):499-513</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24725414</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Sep 8;324(10):951-960</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32789505</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2011 Jun 15;186(12):7264-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21576510</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Aug 14;369(6505):818-823</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32616673</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12300-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25136102</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2019 Sep 5;178(6):1313-1328.e13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31491384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Oct;586(7830):578-582</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32731258</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Oct 15;383(16):1544-1555</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32722908</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Immunol. 2018 Oct;39:14-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29801750</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Immunol. 2020 Jun 19;5(48):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32561559</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Rev. 2016 Nov;274(1):330-353</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27782333</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Public Health. 2006 Sep;96(9):1554-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16873743</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2020 Jun;26(6):932-940</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32393800</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2010 Oct 29;33(4):516-29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21029962</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Aug 15;396(10249):467-478</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32702298</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Oct 29;383(18):1724-1734</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32871063</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 1983 Nov;24(5):713-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6318655</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Hyg. 1958 Jul;68(1):59-65</Citation>
<ArticleIdList><ArticleId IdType="pubmed">13559211</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2020 Nov 25;38(50):7892-7896</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33139139</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 Oct 1;183(1):158-168.e14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32979941</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Microbiol. 2020 Oct 21;58(11):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32826322</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Oct;586(7830):594-599</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32998157</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Nov 12;383(20):1920-1931</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32663912</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2020 Aug;26(8):1200-1204</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32555424</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 Jun 25;181(7):1489-1501.e15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32473127</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2020 Jun;26(6):845-848</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32350462</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Intensive Care Med Exp. 2020 Dec 7;8(1):72</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33284413</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2009 Jan;10(1):116-125</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19029902</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Immunol. 2020 Jun 26;5(48):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32591408</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 May 1;368(6490):473-474</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32303591</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 Oct 1;183(1):143-157.e13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32877699</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Jun 9;323(22):2340-2341</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32401274</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2020 Sep;20(9):529-536</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32728222</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2016 Jun 21;44(6):1379-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27287409</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2017 Jul;17(7):407-420</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28436424</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Aug 25;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32840608</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2014 Sep 18;41(3):478-492</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25220212</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2020 Jun 16;52(6):910-941</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32505227</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Epidemiol Infect. 1990 Oct;105(2):435-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2170159</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2020 May;19(5):305-306</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32273591</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Oct;586(7830):589-593</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32785213</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Aug;584(7819):115-119</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32454513</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2020 Apr;26(4):618-629</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32094927</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Dis Child. 1986 Jun;140(6):543-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3706232</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2008 Oct 15;181(8):5490-500</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18832706</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Sep 26;396(10255):887-897</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32896291</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2014 Jan 17;343(6168):313-317</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24310610</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Aug 21;369(6506):956-963</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32540903</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Nov 12;383(20):1899-1901</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32931679</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Annu Rev Immunol. 2019 Apr 26;37:521-546</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30726153</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Sep 4;369(6508):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32669297</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Jul 15;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32667972</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci China Life Sci. 2020 Aug 28;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32876887</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2015 Dec 15;43(6):1186-98</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26682988</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Nov;587(7833):270-274</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32726801</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2020 Jun;20(6):375-388</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32132681</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Paediatr Respir Rev. 2017 Jun;23:40-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28416135</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Dec 4;370(6521):1227-1230</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33115920</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Rep. 2017 Aug 29;20(9):2251-2261</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28854372</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2020 Oct;26(10):1623-1635</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32807934</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2020 Aug 17;94(17):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32591466</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Jun 13;395(10240):1845-1854</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32450106</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2013 Nov;123(11):4595-611</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24216507</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Dec 10;383(24):2320-2332</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32877576</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 1999 Dec;5(12):1370-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10581078</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Aug;584(7821):443-449</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32668443</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Mol Immunol. 2020 May;17(5):533-535</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32203188</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Commun. 2020 May 20;11(1):2601</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32433465</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1984 Aug;150(2):195-201</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6088646</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Immunol. 2020 Jul 15;5(49):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32669287</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 May 29;368(6494):945-946</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32385100</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2020 May;20(5):565-574</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32213337</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Immunol. 2020 Oct 8;5(52):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33033173</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Aug;584(7821):463-469</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32717743</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2020 Jun;20(6):335-337</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32393823</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2013 Dec;19(12):1597-608</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24309663</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 Sep 17;182(6):1419-1440.e23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32810438</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 Sep 17;182(6):1401-1418.e18</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32810439</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Aug 14;369(6505):806-811</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32434945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cold Spring Harb Perspect Med. 2020 Mar 9;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32152245</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Aug 14;369(6505):812-817</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32434946</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2004 Aug 1;173(3):1978-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15265932</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 May 28;181(5):1036-1045.e9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32416070</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2020 Oct 13;53(4):864-877.e5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32791036</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2015 Jul 1;195(1):17-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26092813</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Immunol. 2020 Oct 8;5(52):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33033172</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Mar 28;395(10229):1033-1034</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32192578</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Aug 7;369(6504):643-650</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32540902</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br Med J. 1967 Sep 23;3(5568):767-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6043624</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Sep 4;369(6508):1210-1220</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32788292</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Immunol. 2020 Nov;21(11):1336-1345</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32887977</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunity. 2020 Jun 16;52(6):971-977.e3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32413330</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 1984;13(2):179-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6319590</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Sep 10;383(11):1085-1087</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32706954</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 Oct 15;183(2):315-323.e9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32941801</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Feb 14;70(5):748-753</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30953061</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 1959 May;38(5):762-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">13654511</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Glob Health. 2018 Dec;6(12):e1386-e1396</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30342925</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Microbe. 2020 Nov;1(7):e283-e289</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33015652</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Aug 7;369(6504):718-724</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32661059</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2020 Apr;26(4):502-505</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32284613</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2017 Feb 28;114(9):2425-2430</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28193898</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2020 Oct;26(10):1636-1643</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32839624</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 1963 Nov 9;186:578-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14059033</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2016 Mar 24;531(7595):523-527</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26982722</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Transl Med. 2020 Sep;8(17):1084</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33145303</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
</list>
<tree><country name="États-Unis"><noRegion><name sortKey="Grigoryan, Lilit" sort="Grigoryan, Lilit" uniqKey="Grigoryan L" first="Lilit" last="Grigoryan">Lilit Grigoryan</name>
</noRegion>
<name sortKey="Pulendran, Bali" sort="Pulendran, Bali" uniqKey="Pulendran B" first="Bali" last="Pulendran">Bali Pulendran</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000207 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000207 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidStanfordV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:33262067
   |texte=   The immunology of SARS-CoV-2 infections and vaccines.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:33262067" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidStanfordV1

This area was generated with Dilib version V0.6.38.
Data generation: Tue Feb 2 21:24:25 2021. Site generation: Tue Feb 2 21:26:08 2021

	Serveur d'exploration sur le Covid à Stanford
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le Covid à Stanford

The immunology of SARS-CoV-2 infections and vaccines.

The immunology of SARS-CoV-2 infections and vaccines.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki